20 completed, 5 active not recruiting, 4 recruiting, 3 not yet recruiting. 16 Phase 2, 14 Phase 3, 7 Not applicable, 4 Phase 4, 1 Phase 1.
Follow Clofazimine: new trials by email Literature Review of Clofazimine trials Research Report on Clofazimine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine - Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection | Phase 1 | Enrolling by invitation | Vancouver Coastal Health | 1 | 2026-01-11 | 2026-06-03 |
| 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province bedaquiline, Delamanid (DLM), Linezolid (LZD) - Treat to Target, Treatment Duration | Not applicable | Not yet recruiting | Wuhan Pulmonary Hospital | 52 | 2025-09-30 | 2025-09-30 |
| A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis bedaquiline, Pretomanid (Pa), linezolid - Efficacy and Safety | Not applicable | Not yet recruiting | Wuhan Pulmonary Hospital | 200 | 2025-09-01 | 2025-08-17 |
| Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients Dapsone - Leprosy, Mycobacterium Leprae Infection | Not applicable | Recruiting | South Valley University | 50 | 2024-12-20 | 2025-02-11 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
| Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 94 | 2023-11-24 | 2026-08-05 |
| Linezolid Dosing Strategies in Drug-Resistant TB Linezolid 600 mg, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW) - Tuberculosis, Multidrug-Resistant, Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 138 | 2022-09-27 | 2026-10-02 |
| Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB Delamanid, Levofloxacin, Bedaquiline - Tuberculosis, Multidrug-Resistant | Phase 2 | Active not recruiting | Boston University | 271 | 2022-06-07 | 2026-07-08 |
| A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China Bedaquiline, Levofloxacin, Linezolid - Tuberculosis, Multidrug-Resistant | Phase 4 | Unknown | Beijing Chest Hospital | 212 | 2022-05-10 | 2023-01-18 |
| Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease Clofazimine - Nontuberculous Mycobacterial Diseases | Phase 2 | Completed | Radboud University Medical Center | 12 | 2022-02-14 | 2023-08-16 |
| Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study Rifapentine, Rifampicin, Isoniazid - HIV, Tuberculosis | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 104 | 2021-11-05 | 2026-07-08 |
| Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS Bedaquiline, Pyrazinamide, Linezolid - Multidrug Resistant Tuberculosis | Not applicable | Completed | Huashan Hospital | 89 | 2021-01-20 | 2024-11-12 |
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease RHB-204, Placebo - Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis | Phase 3 | Terminated | RedHill Biopharma Limited | 12 | 2020-12-01 | 2025-03-18 |
| Economic Evaluation of New MDR TB Regimens Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 73 | 2020-10-20 | 2024-04-22 |
| Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 Interferon beta-1b, Clofazimine - COVID-19 | Phase 2 | Unknown | The University of Hong Kong | 81 | 2020-07-14 | 2020-07-15 |
| Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule - Tuberculosis, Multidrug-Resistant, Tuberculosis | Phase 3 | Completed | Médecins Sans Frontières, France | 323 | 2020-04-06 | 2025-02-10 |
| Finding the Optimal Regimen for Mycobacterium Abscessus Treatment Amikacin, Tigecycline, Imipenem - Pulmonary Disease Due to Mycobacteria (Diagnosis) | Phase 2 / Phase 3 | Recruiting | The University of Queensland | 300 | 2020-03-02 | 2026-05-11 |
| Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Bedaquiline, Pretomanid, Moxifloxacin - Multidrug Resistant Tuberculosis | Completed | Medecins Sans Frontieres, Netherlands | 137 | 2019-09-01 | 2024-05-29 |
Showing 20 of 40. Sign in to see all of them.
Tuberculosis, Multidrug-Resistant (13) · Tuberculosis, Pulmonary (12) · Tuberculosis (9) · Acquired Immunodeficiency Syndrome (5) · Extensively Drug-Resistant Tuberculosis (5) · HIV Infections (5) · Mycobacterium avium-intracellulare Infection (5) · Mycobacterium Infections, Nontuberculous (4) · Leprosy (3) · Lung Diseases (3) · AIDS-Related Opportunistic Infections (2) · Bacterial Infections (2) · Crohn Disease (2) · Mycobacterium Infections (2) · Bronchiectasis (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Medecins Sans Frontieres, Netherlands (4) · Beijing Chest Hospital (2) · Huashan Hospital (2) · Médecins Sans Frontières, France (2) · RedHill Biopharma Limited (2) · The University of Queensland (2) · Wuhan Pulmonary Hospital (2) · Abbott (1) · Beijing Children's Hospital (1) · Boston University (1) · Brigham and Women's Hospital (1) · Global Alliance for TB Drug Development (1) · IUATLD, Inc (1) · Medstar Health Research Institute (1)
South Africa (11) · United States (9) · China (6) · India (5) · Belarus (4) · Philippines (4) · Haiti (3) · Peru (3) · Uzbekistan (3) · Brazil (2) · Canada (2) · Georgia (2) · Israel (2) · Kazakhstan (2) · Lesotho (2)
Carole Mitnick, Sc.D (2) · Lorenzo Guglielmetti, MD (2) · A-Dong Shen, Master (1) · Andreas Diacon, MD (1) · Andrew Nunn, PhD (1) · Benson C (1) · Bern Nyang'wa, MB BS, MPH (1) · Bern-Thomas Nyang'wa, MD (1) · Beverley Stringer (1) · Charles Horsburgh, MD (1) · Chirgwin K (1) · Cohn D (1) · Constance A. Benson (1) · DM Parenti (1) · David Y Graham, MD (1)
PMID 21508125, PMID 23344397, PMID 24077845, PMID 25622149, PMID 26929418, PMID 28222139, PMID 28704363, PMID 29867930, PMID 30102705, PMID 30139372, PMID 30865791, PMID 31676905, PMID 32277809, PMID 34489263, PMID 34489274, PMID 34563240, PMID 34748385, PMID 35028659, PMID 35698158, PMID 36546625, PMID 36808186, PMID 37980911, PMID 38037119, PMID 38462751, PMID 38561815, PMID 38697216, PMID 38842323, PMID 39378281, PMID 39879593, PMID 40064371, PMID 40414233, PMID 40683298, PMID 40915311, PMID 41510291, PMID 41917253, PMID 41925982, PMID 42270675, PMID 42341301
U01AI152980 (1), U01AI170426 (1)